Verrica Pharmaceuticals Verrica Pharmaceuticals’ (VRCA) product YCANTH (cantharidin) is the only commercially available treatment approved by the FDA for the treatment of adults and pediatric patients two years of age and older with Molluscum Contagiosum. Molluscum Contagiosum is a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. The firm’s product VP-102 is in . . . This …
We are currently working to bring into the upcoming ProhostBiotech Letter some small clinical and commercial innovating firms that are challenging the Top-Tier firms that are currently generating billions of dollars in selling revenues. These firms are developers of products for treating type 2 diabetes, obesity and NASH diseases, in addition to clinical stage firms that are challenging the current developers of gene editing diseases …
Verrica Pharmaceuticals Verrica Pharmaceuticals (VRCA) is a dermatology therapeutics company developing medications for skin diseases. Today Verrica announced financial results for the fourth quarter and year ended December 31, 2023. Ted White, Verrica Pharmaceuticals' President and Chief Executive Officer said, “We continued to make considerable progress with the launch of YCANTHTM during our first full quarter of commercial operations. With a growing confidence . …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.